Triple
T22889013
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | CYP2C19 |
E567681
|
entity |
| Predicate | metabolizes |
P37221
|
FINISHED |
| Object | mephenytoin |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: mephenytoin | Statement: [CYP2C19, metabolizes, mephenytoin]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: mephenytoin Context triple: [CYP2C19, metabolizes, mephenytoin]
-
A.
phenytoin
Phenytoin is an antiepileptic medication commonly used to prevent and control seizures by stabilizing neuronal activity in the brain.
-
B.
carbamazepine
Carbamazepine is an anticonvulsant and mood-stabilizing drug commonly used to treat epilepsy, trigeminal neuralgia, and bipolar disorder.
-
C.
valproate
Valproate is an anticonvulsant and mood-stabilizing medication widely used to treat epilepsy, bipolar disorder, and to prevent migraine headaches.
-
D.
lamotrigine
Lamotrigine is an anticonvulsant medication primarily used to treat epilepsy and bipolar disorder by stabilizing neuronal activity and reducing the frequency of seizures or mood episodes.
-
E.
vigabatrin
Vigabatrin is an antiepileptic medication that irreversibly inhibits GABA transaminase to increase brain GABA levels, used mainly for refractory seizures such as infantile spasms but associated with risks like permanent visual field loss.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: mephenytoin Target entity description: Mephenytoin is an anticonvulsant drug historically used to treat epilepsy and known for its role as a probe substrate in pharmacogenetic studies of CYP2C19 enzyme activity.
-
A.
phenytoin
Phenytoin is an antiepileptic medication commonly used to prevent and control seizures by stabilizing neuronal activity in the brain.
-
B.
carbamazepine
Carbamazepine is an anticonvulsant and mood-stabilizing drug commonly used to treat epilepsy, trigeminal neuralgia, and bipolar disorder.
-
C.
valproate
Valproate is an anticonvulsant and mood-stabilizing medication widely used to treat epilepsy, bipolar disorder, and to prevent migraine headaches.
-
D.
lamotrigine
Lamotrigine is an anticonvulsant medication primarily used to treat epilepsy and bipolar disorder by stabilizing neuronal activity and reducing the frequency of seizures or mood episodes.
-
E.
vigabatrin
Vigabatrin is an antiepileptic medication that irreversibly inhibits GABA transaminase to increase brain GABA levels, used mainly for refractory seizures such as infantile spasms but associated with risks like permanent visual field loss.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e2458a92ec81908fc1cd5f6407d2ab |
completed | April 17, 2026, 2:36 p.m. |
| NER | Named-entity recognition | batch_69f17fc37a448190996e106aacc900f4 |
completed | April 29, 2026, 3:49 a.m. |
Created at: April 17, 2026, 3:40 p.m.